Company to review BXCL502 and other potential emerging pipeline candidates
Dr.
Dr.
In addition, the presentation will feature two neuropsychiatry experts:
- Dr,
Jeffrey Cummings ,M.D. Sc .D.:(HC): The Neuropsychiatric Inventory: Measuring Agitation Relief in Alzheimer’s Disease
Dr.Jeffrey Cummings is Research Professor in theDepartment of Brain Health and Director of theChambers-Grundy Center for Transformative Neuroscience at theUniversity of Nevada, Las Vegas . He previously served as Founding Director of theCleveland Clinic Lou Ruvo Center for Brain Health inLas Vegas , Director of theMary S. Easton Center for Alzheimer’sDisease Research , and Director of theDeane F. Johnson Center for Neurotherapeutics , both atUCLA . A world-renowned Alzheimer’s researcher and leader of clinical trials,Dr. Cummings has been recognized with the American Geriatrics Society’s Henderson Award, the national Alzheimer’s Association’sRonald and Nancy Reagan Research Award, and the American Association of Geriatric Psychiatry’s Distinguished Scientist Award. He has published nearly 900 articles and 44 books devoted to neuroscience, Alzheimer’s disease, and clinical trials.
- Dr.
Sandra Comer , Ph.D.: BXCL501 as a Potential Treatment for Opioid Withdrawal
Dr.Sandra Comer is Principal Investigator of the National Institute on Drug Abuse (NIDA)-funded trial of investigational BXCL501 for potential withdrawal treatment of patients diagnosed with opioid use disorder and Professor of Neurobiology in theDepartment of Psychiatry atColumbia University . She is also Director of theOpioid Laboratory in the Division on Substance Use Disorders. Her research focuses on the clinical testing of medications for treating opioid use disorders, devices for treating opioid overdose, methods to maximize the use of naloxone by opioid users, and evaluations of the comparative abuse liability of prescribed pain medications.Dr. Comer served as President of theCollege on Problems of Drug Dependence (CPDD), the longest-standing scholarly society in theU.S. devoted to research on substance use disorders, and is currently CPDD’s Public Policy Officer. She joined theExpert Advisory Panel on Drug Dependence for theWorld Health Organization and has 190 publications on substance use disorders.
Event Access
To access the virtual R&D Day presentation, please dial 877-407-5795 (domestic) or 201-689-8722 (international). A live webcast and presentation materials will be available on the Investors section of the corporate website, bioxceltherapeutics.com, and a webcast replay will be available through
About BXCL501
In indications other than those approved by the
About
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, the date, time and content of the Company’s R&D Day, its proposed development programs, and the potential uses of its product candidates. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended
Contact Information
Corporate
1.203.494.7062
ekopp@bioxceltherapeutics.com
Investor Relations
1.475.355.8462
bdoyle@bioxceltherapeutics.com
Media
Russo Partners
David Schull
T: 858-717-2310
David.schull@russopartnersllc.com
Scott Stachowiak
T: 646-942-5630
Scott.stachowiak@russopartnersllc.com
Source:
*IGALMI is a trademark of
BT BIOXCEL THERAPEUTICS is a registered trademark of
All other trademarks are the properties of their respective owners.
Copyright © 2023, BioXcel Therapeutics, Inc. All rights reserved.
Source:
2023 GlobeNewswire, Inc., source